Multinational Prevalence of Neurological Phenotypes in Patients Hospitalized with COVID-19

OBJECTIVE: Neurological complications can worsen outcomes in COVID-19. We defined the prevalence of a wide range of neurological conditions among patients hospitalized with COVID-19 in geographically diverse multinational populations. METHODS: Using electronic health record (EHR) data from 348 participating hospitals across 6 countries and 3 continents between January and September 2020, we performed a cross-sectional study of hospitalized adult and pediatric patients with a positive SARS-CoV-2 reverse transcription polymerase chain reaction test, both with and without severe COVID-19. We assessed the frequency of each disease category and 3-character International Classification of Disease (ICD) code of neurological diseases by countries, sites, time before and after admission for COVID-19, and COVID-19 severity. RESULTS: Among the 35,177 hospitalized patients with SARS-CoV-2 infection, there was increased prevalence of disorders of consciousness (5.8%, 95% confidence interval [CI]: 3.7%−7.8%, pFDR<.001) and unspecified disorders of the brain (8.1%, 95%CI: 5.7%−10.5%, pFDR<.001), compared to pre-admission prevalence. During hospitalization, patients who experienced severe COVID-19 status had 22% (95%CI: 19%−25%) increase in the relative risk (RR) of disorders of consciousness, 24% (95%CI: 13%−35%) increase in other cerebrovascular diseases, 34% (95%CI: 20%−50%) increase in nontraumatic intracranial hemorrhage, 37% (95%CI: 17%−60%) increase in encephalitis and/or myelitis, and 72% (95%CI: 67%−77%) increase in myopathy compared to those who never experienced severe disease. INTERPRETATION: Using an international network and common EHR data elements, we highlight an increase in the prevalence of central and peripheral neurological phenotypes in patients hospitalized with SARS-CoV-2 infection, particularly among those with severe disease.


Supplementary Statistical Methods and Equations
For each neurological ICD code (3 alphanumeric characters), we reported the total count across all sites and all countries (Y) as well as the proportion of patients hospitalized with COVID-19 who had each code at each site (and each country), both before admission (propbefore) and after admission (propafter) (eEq. 1).
We next compared the prevalence of each neurological ICD code (first three characters) and disease category by site, before and after admission date, between patients who ever met the criteria of severe COVID-19 and those who did not. For each ICD code X, we computed the expected number of ever-severe patient cases D-with: where ? denotes the observed number of never-severe patient cases with code X, and ? denotes the observed number of ever-severe patient cases with code X (eEq. represents the proportion of patients without severe disease but with neurological code X. We then performed an enrichment analysis to examine the difference in proportions of ever-severe disease across neurological ICD codes. Specifically, we calculated the enrichment of each neurological ICD code by dividing the observed number of severe cases by the expected number of severe cases and reported a value of log2 enrichment (LOE) and its 95% confidence interval (eEq. 4).

LOE =
We estimated the 95% confidence interval of the LOE using the Poisson model method. Finally, we computed the p values using Fisher's exact test and corrected for multiple hypothesis testing with Benjamini-Hochberg's false discovery rate (FDR) procedure. We considered a result with pFDR<0.05 statistically significant.

Exploratory Analysis of ICD-9 Data
We analyzed separately the neurological phenotypes among the subset of the patients with ICD-9 codes, as a minority of the 4CE sites in the USA (7 sites) and Italy (4 sites) reported neurological ICD-9 codes (eTable 2). Because 7 of these sites reported both ICD-9 and ICD-10 data and given the aggregate data format, we could not ascertain the exact number of patients with ICD-9 data. We separated this analysis from the main ICD-10 analysis because one-to-one mapping from ICD-9 to ICD-10 codes was not available for all codes.
Similar to the ICD-10 data, there was increased prevalence of "disorders of consciousness and other neurological conditions" in patients after admission date when compared to before admission date (eFig. 2, eFig. 3). These differences appear to be driven by the US sites. However, there was no statistically significant difference when examining the change in prevalence of individual neurological conditions after admission date. The smaller sample size might explain the difference from the ICD-10 data results.
Finally, there was a significantly lower proportion of patients with "other and ill-defined cerebrovascular disease" (ICD-9 437: RDDafter=-42%) among patients with severe disease in the period after admission date. However, we must interpret these findings with great caution given the limitations of the ICD-9 data and the inconsistency with the larger sample size of the ICD-10 data. eTable 1. Neurological disease categories, corresponding ICD-9 codes, and their descriptions for the exploratory analysis.  Log2 enrichment (LOE) and 95% confidence interval for each ICD-10 code (left) and the absolute difference between the observed (▴) and expected (•) number of severe cases (right) after admission. A purple positive LOE value for an ICD-9 code indicates a statistically significantly higher proportion of severe cases with the given ICD-10 code when compared to the never-severe cases. Conversely, a green negative LOE value indicates a statistically significantly lower proportion of severe cases with the given ICD-10 code compared to the neversevere cases. Neurological ICD-10 codes are ordered based on the expected number of severe cases after admission date across all sites. The results are generally consistent between the US sites and the non-US sites, except for the following: (1) ICD-10 code R43 (Disturbances of smell and taste) displays opposite directions between the US sites (higher proportion of severe cases with R43) and the non-US sites (lower proportion of severe cases with R43); (2) The US sites have several significant findings that are not significant among the non-US sites, largely due to the smaller number of sites outside the US. Overall, the findings from the subgroup analyses between US and non-US sites are consistent with the findings from the pooled analysis (Fig. 4, main text). eFigure 4. Prevalence of neurological phenotypes among all patients by ICD-9 code.

Disease Category ICD-9 ICD-9 Description
(A) Difference in prevalence of each neurological ICD-9 code by site and country, calculated as after admission date -before admission date (Eq. 2). The absolute values of prevalence are displayed in eFig. 3. (B) Per ICD-9 code, total counts of patients at all sites (left) and average proportion of patients (right) before and after admission date. Mean prevalence estimates across sites are shown as circles and their 95% confidence intervals as bars. ICD-9 codes are ordered based on the mean prevalence difference between before and after admission date.